Site Map

Alternative Medicine »

Morphosys And Galapagos Enter Alliance To Co-develop Novel Therapeutic Antibodies In Bone And Joint Disease

Wed, 26 Nov 2008 Similar Items Print Press Release Submissions »

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies - - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Galapagos NV (Euronext: GL… Read »

 

Similar Items:
Galapagos And Glaxosmithkline Expand Osteoarthritis AllianceGalapagos And Glaxosmithkline Expand Osteoarthritis Alliance
Galapagos Enters Strategic Alliance In Diabetes And Obesity With Merck & Co., Inc.Galapagos Enters Strategic Alliance In Diabetes And Obesity With Merck & Co., Inc.
Anadis Launches Products To Reduce Global Childhood Diarrhea Deaths - Oral Rotavirus & E.coli Antibodies: Immediate Acting Anadis Launches Products To Reduce Global Childhood Diarrhea Deaths - Oral Rotavirus & E.coli Antibodies: Immediate Acting "passive" Immunity Against Virus And Toxinsexpands Disease Control Options
Nu Skin Enterprises And Toyo Bio-pharma Enter Agreement For Joint Product Research And DevelopmentNu Skin Enterprises And Toyo Bio-pharma Enter Agreement For Joint Product Research And Development
Influenza Antibody Spray Success: Opens New Approach To Respiratory Disease ControlInfluenza Antibody Spray Success: Opens New Approach To Respiratory Disease Control
Galapagos Enters Into Oncology Target Discovery Collaboration With Janssen PharmaceuticaGalapagos Enters Into Oncology Target Discovery Collaboration With Janssen Pharmaceutica
Nutracea Forms Joint Ventures With Herbalscience To Develop Nutraceutical Extracts And Pharmaceutical Chemistries From Stabilized Rice BranNutracea Forms Joint Ventures With Herbalscience To Develop Nutraceutical Extracts And Pharmaceutical Chemistries From Stabilized Rice Bran
Algaecal Launches Free Bone Health Calculator SoftwareAlgaecal Launches Free Bone Health Calculator Software
King Pharmaceuticals And Acura Pharmaceuticals Enter Agreement To Develop And Commercialize Immediate Release Pain Medicines Utilizing ACURA’S Aversion(r) (abuse-deterrent) TechnologyKing Pharmaceuticals And Acura Pharmaceuticals Enter Agreement To Develop And Commercialize Immediate Release Pain Medicines Utilizing ACURA’S Aversion(r) (abuse-deterrent) Technology
Mendelsohn Honored For Taking New Therapy From Concept To ClinicMendelsohn Honored For Taking New Therapy From Concept To Clinic